Global Ganja Report

Something of a corporate scramble is underway to secure patents for the various curative properties of CBD, and associated products and procedures. Pharmaceutical firms see a windfall, but some activists raise concerns about the creeping privatization of a cannabinoid that should belong to the genetic and intellectual commons of the human race. How realistic are fears about the imminent arrival of "corporate cannabis"?

With US stock exchanges still almost entirely closed to cannabis businesses, the stateside industry is increasingly seeking access to the Canadian exchanges in order to secure investment. Taking over publicly traded Canadian firms through reverse mergers has emerged as the critical tactic in this endeavor.

Around the world, mothers are on the frontlines of demanding legal access to cannabis products for their children who suffer from epilepsy and other ailments. Often, these courageous moms have risked their freedom to provide medicine for their offspring. Sometimes they have actually shamed the authorities into changing the law—but still face the prospect of prison time.

A federal appeals court has turned down a challenge by the cannabis industry to the DEA's official finding that CBD is a controlled substance. But questions about whether CBD should be treated as a controlled substance remain pending at the state level.

A recent study about the impact of cannabinoids on bone density is raising concerns about possible ill effects on longterm heavy marijuana smokers. Earlier studies, however, showed potential for certain cannabinoids in treating bone fractures. The relationship between cannabis and bone-building function may be more complicated than recent media reports suggest.

Reports indicate that promoters of a popular initiative for a medical marijuana law in Utah have won enough signatures to get their proposal before the state's voters in November. A far more restrictive law allowing use of CBD preparations is meanwhile before the state house. The ballot initiative would make the legislation basically irrelevant—but faces stiff opposition.

Several bills now pending before the Colorado state house will further shape what the legal cannabis economy will look like in the Centennial State—for better or for worse. While some of these measures would mean a freer atmosphere both for "recreational" and medicinal users, others may portend greater big-money control of the fast-growing industry.

Seniors are the fastest growing group of medicinal cannabis users in the coutry, and a growing number of nursing homes from coast to coast are tolerating use of tinctures and extracts to combat dementia, insomnia and related ailments. Patient testimony is now backed up by research, with scientists identifying the mechanism by which cannabinoids slow the deterioration of neurons in the brain. But federal strictures continue to pose an obstacle to investigation—leaving medicinal users in the cold under US law.